Jennifer L Beaumont1, John M Salsman2,3, Jose Diaz4, Keith C Deen5, Lauren McCann5, Thomas Powles6, Michelle D Hackshaw7, Robert J Motzer8, David Cella1,9. 1. Department of Medical Social Sciences, Northwestern University Feinberg School of Medicine, Chicago, Illinois. 2. Department of Social Sciences and Health Policy, Wake Forest School of Medicine, Winston-Salem, North Carolina. 3. Comprehensive Cancer Center at Wake Forest Baptist, Winston-Salem, North Carolina. 4. Novartis Pharma AG, Basel, Switzerland. 5. GlaxoSmithKline, Collegeville, Pennsylvania. 6. Barts Cancer Institute, London, United Kingdom. 7. Novartis Pharma Services AG, Basel, Switzerland. 8. Memorial Sloan Kettering Cancer Center, New York, New York. 9. Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, Illinois.
Abstract
BACKGROUND: In a phase 3, randomized, open-label trial (Pazopanib versus Sunitinib in the Treatment of Locally Advanced and/or Metastatic Renal Cell Carcinoma, COMPARZ; NCT00720941), pazopanib was found to be noninferior to sunitinib in terms of progression-free survival in patients with metastatic renal cell carcinoma with no prior therapy. Overall treatment differences were evaluated in a post hoc analysis with a quality-adjusted time without symptoms or toxicity (Q-TWiST) methodology. METHODS: Each patient's overall survival was partitioned into 3 mutually exclusive health states: time with grade 3 or 4 toxicity (TOX), time without symptoms of disease or grade 3/4 toxicity of treatment, and time after tumor progression or relapse (REL). The time spent in each state was weighted by a health-state utility associated with that state and summed to calculate the Q-TWiST. A threshold utility analysis was used, and utilities were applied across the range of 0 (similar to death) to 1 (perfect health). RESULTS: A total of 1110 patients were enrolled (557 on pazopanib and 553 on sunitinib). The mean TOX was 31 days (95% confidence interval, 13-48 days) longer for sunitinib versus pazopanib. In the threshold utility analysis, the difference in the Q-TWiST ranged from -11 days (utility for TOX, 1; utility for REL, 0) to 43 days (utility for TOX, 0; utility for REL, 1) in favor of pazopanib across most utility combinations. Differences were significant in less than half of the utility combinations examined, and this typically occurred when the utility for TOX was lower than the utility for REL. CONCLUSIONS: Patients randomized to pazopanib had a slightly longer Q-TWiST in comparison with sunitinib patients, and this was primarily due to the reduced length of TOX.
RCT Entities:
BACKGROUND: In a phase 3, randomized, open-label trial (Pazopanib versus Sunitinib in the Treatment of Locally Advanced and/or Metastatic Renal Cell Carcinoma, COMPARZ; NCT00720941), pazopanib was found to be noninferior to sunitinib in terms of progression-free survival in patients with metastatic renal cell carcinoma with no prior therapy. Overall treatment differences were evaluated in a post hoc analysis with a quality-adjusted time without symptoms or toxicity (Q-TWiST) methodology. METHODS: Each patient's overall survival was partitioned into 3 mutually exclusive health states: time with grade 3 or 4 toxicity (TOX), time without symptoms of disease or grade 3/4 toxicity of treatment, and time after tumor progression or relapse (REL). The time spent in each state was weighted by a health-state utility associated with that state and summed to calculate the Q-TWiST. A threshold utility analysis was used, and utilities were applied across the range of 0 (similar to death) to 1 (perfect health). RESULTS: A total of 1110 patients were enrolled (557 on pazopanib and 553 on sunitinib). The mean TOX was 31 days (95% confidence interval, 13-48 days) longer for sunitinib versus pazopanib. In the threshold utility analysis, the difference in the Q-TWiST ranged from -11 days (utility for TOX, 1; utility for REL, 0) to 43 days (utility for TOX, 0; utility for REL, 1) in favor of pazopanib across most utility combinations. Differences were significant in less than half of the utility combinations examined, and this typically occurred when the utility for TOX was lower than the utility for REL. CONCLUSIONS:Patients randomized to pazopanib had a slightly longer Q-TWiST in comparison with sunitinibpatients, and this was primarily due to the reduced length of TOX.
Authors: Michael K Wong; Ateesha F Mohamed; A Brett Hauber; Jui-Chen Yang; Zhimei Liu; Jaqueline Rogerio; Carlos A Garay Journal: J Med Econ Date: 2012-07-18 Impact factor: 2.448
Authors: Paul Swinburn; Andrew Lloyd; Paul Nathan; Toni K Choueiri; David Cella; Maureen P Neary Journal: Curr Med Res Opin Date: 2010-05 Impact factor: 2.580
Authors: Robert J Motzer; Thomas E Hutson; David Cella; James Reeves; Robert Hawkins; Jun Guo; Paul Nathan; Michael Staehler; Paul de Souza; Jaime R Merchan; Ekaterini Boleti; Kate Fife; Jie Jin; Robert Jones; Hirotsugu Uemura; Ugo De Giorgi; Ulrika Harmenberg; Jinwan Wang; Cora N Sternberg; Keith Deen; Lauren McCann; Michelle D Hackshaw; Rocco Crescenzo; Lini N Pandite; Toni K Choueiri Journal: N Engl J Med Date: 2013-08-22 Impact factor: 91.245
Authors: Michael Friedlander; Val Gebski; Emma Gibbs; Lucy Davies; Ralph Bloomfield; Felix Hilpert; Lari B Wenzel; Daniel Eek; Manuel Rodrigues; Andrew Clamp; Richard T Penson; Diane Provencher; Jacob Korach; Tomasz Huzarski; Laura Vidal; Vanda Salutari; Clare Scott; Maria Ornella Nicoletto; Kenji Tamura; David Espinoza; Florence Joly; Eric Pujade-Lauraine Journal: Lancet Oncol Date: 2018-07-17 Impact factor: 41.316
Authors: Shruti Choudhary; Arpit Doshi; Lerin Luckett-Chastain; Michael Ihnat; Ernest Hamel; Susan L Mooberry; Aleem Gangjee Journal: Bioorg Med Chem Date: 2021-02-12 Impact factor: 3.641
Authors: U Batra; P M Parikh; K Prabhash; H B Tongaonkar; P Chibber; D Dabkara; C Deshmukh; N Ghadyalpatil; S Hingmire; A Joshi; S K Raghunath; S Rajappa; R Rajendranath; S K Rawal; Manisha Singh; R Singh; S P Somashekhar; R Sood Journal: South Asian J Cancer Date: 2016 Oct-Dec
Authors: Vincent Berry; Laurent Basson; Emilie Bogart; Olivier Mir; Jean-Yves Blay; Antoine Italiano; François Bertucci; Christine Chevreau; Stéphanie Clisant-Delaine; Bernadette Liegl-Antzager; Emmanuelle Tresch-Bruneel; Jennifer Wallet; Sophie Taieb; Emilie Decoupigny; Axel Le Cesne; Thomas Brodowicz; Nicolas Penel Journal: Cancer Date: 2017-03-10 Impact factor: 6.860
Authors: Jean Gabriel de Souza; Katia L.P. Morais; Eduardo Anglés-Cano; Pamela Boufleur; Evandro Sobroza de Mello; Durvanei Augusto Maria; Clarice Silvia Taemi Origassa; Hamilton de Campos Zampolli; Niels Olsen Saraiva Câmara; Carolina Maria Berra; Rosemary Viola Bosch; Ana Marisa Chudzinski-Tavassi Journal: Oncotarget Date: 2016-09-20